Eplerenone: Difference between revisions
Jump to navigation
Jump to search
imported>Caesar Schinas m (Bot: Update image code) |
imported>Robert Badgett No edit summary |
||
| Line 3: | Line 3: | ||
'''Eplerenone''' is an [[aldosterone receptor]] agonist, similar to [[spironolactone]]. Because it inhibits the negative regulatory feedback of [[aldosterone]] on [[renin]] secretion, increased plasma renin, and serum aldosterone, occur with its use. Eplerenone selectively binds to [[mineralocorticoid receptors]] relative to its binding to [[glucocorticoid]], [[progesterone]] and [[androgen]] receptors. | '''Eplerenone''' is an [[aldosterone receptor]] agonist, similar to [[spironolactone]]. Because it inhibits the negative regulatory feedback of [[aldosterone]] on [[renin]] secretion, increased plasma renin, and serum aldosterone, occur with its use. Eplerenone selectively binds to [[mineralocorticoid receptors]] relative to its binding to [[glucocorticoid]], [[progesterone]] and [[androgen]] receptors. | ||
==Uses== | |||
Eplerenone may help patients with mild<ref name="pmid21073363">{{cite journal| author=Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al.| title=Eplerenone in patients with systolic heart failure and mild symptoms. | journal=N Engl J Med | year= 2011 | volume= 364 | issue= 1 | pages= 11-21 | pmid=21073363 | doi=10.1056/NEJMoa1009492 | pmc= | url= }} </ref> or moderate-to-severe<ref name="pmid12668699">{{cite journal| author=Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al.| title=Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. | journal=N Engl J Med | year= 2003 | volume= 348 | issue= 14 | pages= 1309-21 | pmid=12668699 | doi=10.1056/NEJMoa030207 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12668699 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12899810 Review in: J Fam Pract. 2003 Aug;52(8):598-9] [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12954024 Review in: ACP J Club. 2003 Sep-Oct;139(2):32] </ref> symptoms. | |||
== External links == | == External links == | ||
{{CZMed}} | {{CZMed}} | ||
==References== | |||
<references/> | |||
Revision as of 10:13, 4 February 2011
Eplerenone is an aldosterone receptor agonist, similar to spironolactone. Because it inhibits the negative regulatory feedback of aldosterone on renin secretion, increased plasma renin, and serum aldosterone, occur with its use. Eplerenone selectively binds to mineralocorticoid receptors relative to its binding to glucocorticoid, progesterone and androgen receptors.
Uses
Eplerenone may help patients with mild[1] or moderate-to-severe[2] symptoms.
External links
The most up-to-date information about Eplerenone and other drugs can be found at the following sites.
- Eplerenone - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Eplerenone - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Eplerenone - Detailed information from DrugBank.
References
- ↑ Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. (2011). "Eplerenone in patients with systolic heart failure and mild symptoms.". N Engl J Med 364 (1): 11-21. DOI:10.1056/NEJMoa1009492. PMID 21073363. Research Blogging.
- ↑ Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. (2003). "Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.". N Engl J Med 348 (14): 1309-21. DOI:10.1056/NEJMoa030207. PMID 12668699. Research Blogging. Review in: J Fam Pract. 2003 Aug;52(8):598-9 Review in: ACP J Club. 2003 Sep-Oct;139(2):32